Get the Stockscreener App
55.40
0.63%
-0.35
Akero Therapeutics Inc stock is traded at $55.40, with a volume of 947.39K.
It is down -0.63% in the last 24 hours and up +42.53% over the past month.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
See More
Previous Close:
$55.75
Open:
$55.4
24h Volume:
947.39K
Relative Volume:
0.64
Market Cap:
$4.35B
Revenue:
-
Net Income/Loss:
$-269.44M
P/E Ratio:
-14.77
EPS:
-3.75
Net Cash Flow:
$-262.63M
1W Performance:
+1.61%
1M Performance:
+42.53%
6M Performance:
+80.99%
1Y Performance:
+141.82%
1-Day Range:
$54.43
$56.49
1-Week Range:
$51.42
$56.49
52-Week Range:
$21.02
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Name
Akero Therapeutics Inc
Sector
Industry
Phone
650-487-6488
Address
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Compare AKRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
55.40 | 4.35B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-27-25 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-24 | Initiated | Citigroup | Buy |
| Apr-22-24 | Resumed | BofA Securities | Neutral |
| Sep-19-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-23 | Initiated | UBS | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-14-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Initiated | Guggenheim | Buy |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Jul-20-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-02-20 | Initiated | H.C. Wainwright | Buy |
| Feb-10-20 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Evercore ISI | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
| Jul-15-19 | Initiated | Jefferies | Buy |
| Jul-15-19 | Initiated | ROTH Capital | Buy |
View All
Akero Therapeutics Inc Stock (AKRO) Latest News
Akero Therapeutics (NASDAQ:AKRO) Trading Down 3.3%Here's What Happened - MarketBeat
Don't Ignore The Insider Selling In Akero Therapeutics - simplywall.st
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 2,803 Shares of Stock - MarketBeat
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells 2,493 Shares of Stock - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $127,332.00 in Stock - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO Sells $151,387.96 in Stock - MarketBeat
Rhumbline Advisers Purchases 5,001 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Millennium Management LLC Lowers Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics (AKRO) Emerges as Attractive Acquisition Targ - GuruFocus
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by SG Americas Securities LLC - MarketBeat
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased By Stocktwits - Investing.com India
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased - MSN
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $668,625.00 in Stock - MarketBeat
Investors Buy Large Volume of Call Options on Akero Therapeutics (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $1,376,000.00 in Stock - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy Sells 919 Shares - MarketBeat
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Sells 37,837 Shares of Stock - MarketBeat
Akero Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
(AKRO) Technical Data - news.stocktradersdaily.com
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Transcript : Akero Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 02 - marketscreener.com
Day 8 of Gains Streak for Akero Therapeutics Stock with 21% Return (vs. 97% YTD) [6/9/2025] - Trefis
MASH Market Size in the 7MM was ~USD 1.8 billion in 2023, is projected to grow at a CAGR of 24%, estimates DelveInsight - The Globe and Mail
Akero Therapeutics' Chief Scientific Officer Sells Shares - TradingView
Rumor Fuels Akero Therapeutics (AKRO) Stock Movement | AKRO Stoc - GuruFocus
Rumor Fuels Akero Therapeutics (AKRO) Stock Movement | AKRO Stock News - GuruFocus
Ameriprise Financial Inc. Purchases Shares of 15,172 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy Sells 4,000 Shares - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2025-06-08 | Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation | NDAQ:AKRO | Press Release - Stockhouse
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Bank of America Corp DE Sells 93,294 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Day 7 of Gains Streak for Akero Therapeutics Stock with 20% Return (vs. 95% YTD) [6/6/2025] - Trefis
Ionis Pharmaceuticals (NASDAQ:IONS) versus Akero Therapeutics (NASDAQ:AKRO) Financial Contrast - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect - ACCESS Newswire
Ameriprise Financial Inc. Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics Elects New Directors at Annual Meeting - TipRanks
Two Sigma Advisers LP Acquires 27,200 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Bank of America Corp DE Has $1.84 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Akero Therapeutics Brings Breakthrough Metabolic Disease Pipeline to Goldman Sachs Healthcare Conference - Stock Titan
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Akero Therapeutics Inc Stock (AKRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):